Eminence Biotechnology (Suzhou) Co. has announced that its state-of-the-art facility for the commercial production of cell culture media is now fully operational. The opening aims to address the rapidly growing demand for high-quality media in the fields of vaccines, gene therapies, cell therapies, antibodies, and recombinant proteins.

Located at the BIOBAY Phase II, Suzhou Industrial Park, China, the new facility occupies approximately 7,000 square meters and comprises dedicated zones for media production, warehousing, and laboratory functions. With three dry powder production lines and two liquid production lines, the facility boasts an annual output of up to 20 million liters of dry powder media and 300,000 liters of liquid media.

Equipped with cutting-edge vertical pin-milling manufacturing technology and bolstered by world-class utility systems, the new facility adheres to international GMP standards, ISO9001, and ISO13485 regulations. It is designed to provide biopharmaceutical companies worldwide with consistently high-quality, batch-to-batch stable cell culture media products.